(EMAILWIRE.COM, August 09, 2018 ) The report "Biosurgery Market by Product (Fibrin & Collagen Sealant, Hemostats, Adhesion Barriers, Biological Meshs, Soft Tissue Attachments, Stapler, Bone Graft Substitutes) Application (Orthopedic, Gynecology, Cardiovascular, Reconstructive) - Forecast to 2023", The biosurgery market is expected to reach USD 15.58 billion by 2023 from an estimated USD 11.36 billion in 2018, at a CAGR of 6.5 %. Currently, the global biosurgery market is driven by the rising geriatric population, increase in the volume of surgeries and sports-related and trauma injuries, increasing clearance of biosurgery products by regulatory authorities and growing need for effective blood loss management in patients. However, the high price of biosurgery products and rising cost of surgical procedures may restrict the growth of this market during the forecast period to a certain extent.

Browse 352 market data Tables and 56 Figures spread through 314 Pages and in-depth TOC on "Biosurgery Market".

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=166922302

Objectives of the study

To define, describe, and forecast the biosurgery market by product, application, and region
To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the biosurgery market in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
To profile the key players in the biosurgery market and comprehensively analyze their core competencies
To track and analyze competitive developments such as acquisitions, expansions, and patent or regulatory approvals of key players in the biosurgery market

Some of the major players operating in this market include Baxter International, Inc. (US), C.R. Bard, Inc. (US), Johnson & Johnson (US), Medtronic plc (Ireland), Sanofi Group (France), B. Braun Melsungen AG (Germany), MAQUET Holding B.V. & Co. KG. (Germany), CryoLife, Inc. (US), Stryker Corporation (US), Hemostasis, LLC. (US), Integra Lifesciences Holdings Corporation (US), Cohera Medical Inc. (US), Pfizer Inc. (US), and CSL Limited (Australia).

North America accounted for the largest share of the biosurgery market in 2017, followed by Europe. Increase in the incidence of chronic diseases associated with aging population, increase in the volume of surgical procedures, well-established healthcare services, higher public and private healthcare expenditure, and adoption of highly advanced technology are responsible for the largest share of North America in the biosurgery market.

Know More: https://www.marketsandmarkets.com/PressReleases/biosurgery.asp